Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Wednesday, July 26, 2017
 
Recommended for you
'Sparks' A-Flyin'
Seeking Alpha • Strong Bio
3 Things In Biotech You Should Learn Today: July 25, 2017
Seeking Alpha • Zach Hartman
Samsung Leaps Into Its First U.S. Biosimilars Battle
Seeking Alpha • E.P. Vantage
'Longevity Marketplace' Tech On Display At Boomer Venture Summit
Forbes • Contributor, Next Avenue
HIV: End of Triple-Drug Therapy? (CME/CE)
MedPage Today • Michael Smith
Gilead Puts Up The Good Fight Once Again
Seeking Alpha • Long Term Bio
Patient-generated data could be the missing piece to new payment models for drugs and devices
FierceHealthcare • Evan Sweeney
‘Protect Medicare Now’ campaign is an industry-backed attempt to squash one of the few ways to control health care spending
HealthNewsReview.org • Joy Victory
Walgreens Signs Global Manufacturing Deal With Fareva
Forbes • Bruce Japsen, Contributor
Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs
Xconomy • Bruce V. Bigelow
 
Recommended for You
Epidemiology, Health Finance
'Sparks' A-Flyin'
Seeking AlphaStrong Bio
Summary Lead candidate Luxterna could reach markets for biallelic RPE65-mediated inherited retinal disease in 2017, pending FDA review. The company is making headway in hemophilia B in early to mid-stage clinical trials for candidate SPK-9001, partnered with Pfizer. The company's partnership with...
Share
Cancer, Health Finance
3 Things In Biotech You Should Learn Today: July 25, 2017
Seeking AlphaZach Hartman
Summary Tocagen is a priority for Europe in brain cancer. Celgene amends protocol to join up with Novocure in glioblastoma. Pfizer getting close with its own biosimilar bevacizumab? Welcome to another edition of "3 Things in Biotech You Should Learn Today," a...
Share
Health Finance, Merck & Co., Inc.
Samsung Leaps Into Its First U.S. Biosimilars Battle
Seeking AlphaE.P. Vantage
Johnson & Johnson (NYSE:JNJ) has so far avoided the worst from biosimilar competition to Remicade, but this could be about to change with a new US entrant from Merck & Co. (NYSE:MRK) and Samsung Bioepis. The companies have said the cost of...
Share
AARP, Pfizer, Inc.
'Longevity Marketplace' Tech On Display At Boomer Venture Summit
ForbesContributor, Next Avenue
Indications from the Silicon Valley Boomer Venture Summit are that companies large and small are looking to invest in “the longevity marketplace.”
Share
Health Care Industry, Pfizer, Inc.
HIV: End of Triple-Drug Therapy? (CME/CE)
MedPage TodayMichael Smith
PARIS -- With more powerful anti-HIV drugs, the triple therapy paradigm might be changing, researchers suggested. Two studies, one conducted in the U.S. and one in Argentina, showed promising efficacy for different two-drug regimens, investigators told at an oral session here at...
Share
GlaxoSmithKline plc, Health Finance
Gilead Puts Up The Good Fight Once Again
Seeking AlphaLong Term Bio
Summary Positive phase 3 results outlines the basis for FDA and EMA approval. TRIUMEQ proves a valuable challenge to the Bictegravir along with Truvada drug combination. Company is highly focused on the future of its HIV franchise as its HCV compound faces...
Share
Credit Cards, Credit Services
Patient-generated data could be the missing piece to new payment models for drugs and devices
FierceHealthcareEvan Sweeney
A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. A major part of that initiative will be defining...
Share
Affordable Care Act, Health Care Costs
‘Protect Medicare Now’ campaign is an industry-backed attempt to squash one of the few ways to control health care spending
HealthNewsReview.orgJoy Victory
Lost in the Beltway media morass of the GOP health plan and Trump Jr. is the fate of a little-known provision of the Affordable Care Act (ACA) that offers a pathway for Medicare to control its costs. It’s the Independent Payment Advisory...
Share
Brand Management, Health Care Industry
Walgreens Signs Global Manufacturing Deal With Fareva
ForbesBruce Japsen, Contributor
Walgreens Boots Alliance has signed a deal with Fareva, a large contract manufacturer of cosmetics, pharmaceuticals and household products to make its “beauty brands and private label products.” “The proposed agreement will create a partnership to provide Walgreens Boots Alliance with a...
Share
Asthma, Cancer
Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs
XconomyBruce V. Bigelow
San Diego — San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 million in new venture capital funding. The Series C financing, led by Pfizer Venture Investments, brings total funding for Effector to about $150 million, CEO Steve Worland...
Share